Global Gene Prediction Tool Market - 2023-2030

Global Gene Prediction Tool Market - 2023-2030

Global gene prediction tool market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global gene prediction tool market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Basically, gene prediction involves identifying genes along the genome. The process of locating the areas of genomic DNA which encode genes is sometimes referred to as gene discovery. Genes that code for proteins, RNA, and other functional components like regulatory genes are included in this.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced software or services and boost the global gene prediction tool market. The respective innovative products includes the use of novel tools such as JIGSAW, GENEID for drug discovery.

Market Dynamics: Drivers & Restraints

Growing collaborations and initiatives

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for gene prediction tool owing to the rising research. Various product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On January 18, 2022, Thermo Fisher Scientific and Oncocyte Corporation have entered into a development and collaborative marketing arrangement for a pair distributed in vitro diagnostic (IVD) assessments on the Ion Torrent Genexus System. A precision diagnostics company, Oncocyte Corporation, improving patient outcomes by delivering clear insights that inform crucial decisions in the detection, management, and monitoring of cancer.

Additionally, on July 20, 2023, in order to develop epigenetic drugs using zinc finger proteins (ZFPs) for DNA recognition which is sequence-specific, a clinical-stage genomic medicine company, Sangamo Therapeutics, Inc., and Chroma Medicine, Inc., a genomic medicine company that invented single-dose epigenetic editing treatments, have entered into a research assessment, option, and license agreement.

Furthermore, the rising utilization of novel technology and software for the management of several diseases. Rising awareness among people and increasing research for innovative diagnostic or treatment product development will be a major factor driving the growth of the gene prediction tools market.

Limitations associated with the gene prediction tools

Recent reviews have brought attention to the fact that protein-coding genes are still difficult for automated genome annotation methods to appropriately identify. Significant amounts of genetic sequence divergence, the intricacy of eukaryotic exon mapping, the state of the draft genome assemblies, or variations from classical genetic traits could all be factors in this failure.

Therefore, it is crucial to compare the many gene prediction algorithms now in use in order to gauge their dependability, pinpoint the most promising tactics, as well as to stop the propagation of mistakes in protein databases.

For more details on this report - Request for Sample

Segment Analysis

The global gene prediction tool market is segmented based on component, method, application, end user and region.

Ab-Initio Prediction segment accounted for approximately 59% of market share

In the absence of an experimentally solved structure for a related or homologous protein, a technique known as ab initio prediction of protein structures can be used to ascertain the tertiary structure of a protein. This approach creates protein structure that is influenced by energy function. The difficult endeavor of predicting protein structures solely from sequence data and without the use of templates is known as ab initio prediction.

It is frequently broken down into two independent sub-problems: the method of exploring the conformational space and the scoring system that can discriminate native or native-like structures from non-native ones. A reliable scoring system that can always direct a search towards the native fold doesn't exist yet, and there is no universal search strategy that can provide a sizeable sample of near-natives. Pathway models integrate the search and the scoring function.

According to Briefings in Bioinformatics in 2021, a program called TSSFinder was used to describe the promoter sequences from Eukaryotic species. The initial transcription start site (TSS) prediction approach that uses a probabilistic model based on linear chain conditional random fields (LCCRFs) is TSSFinder, which was originally disclosed in the literature. TSSFinder may be tailored to new organisms and is more accurate than previously released tools.

Geographical Penetration

North America accounted for around 37% of market share in 2022

Due to the rising need for gene prediction tool in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for gene prediction tool.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of tool for research, and increase in biopharmaceutical or bioinformatics business establishment across the region are also contributing to the growth of gene prediction tool market share of this region. The market in this area is growing as people become more aware of various novel innovative tools. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global gene prediction tool market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for gene prediction tool in the U.S. United States have been proactive in executing several initiatives or researches, stimulating gene prediction tool demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene prediction tool market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for gene prediction tool. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global gene prediction tool market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for iinovative tools, like ab-initio prediction tools.

Key Developments
• On June 1, 2023, the new PrimateAI-3D artificial intelligence (AI) algorithm, developed by Illumina Inc., an innovator in DNA sequencing as well as array-based technologies, predicts disease-causing genetic variants in patients with unparalleled accuracy. Two papers outlining the development of the algorithm and its implementation to fifty thousand genomes in the United Kingdom Biobank cohort were published in Science on June 2 (issue 6648) with the results.
• On January 23, 2023, By incorporating game-changing evaluation speed to assess and comprehend whole exome sequencing (WES), whole genome sequencing (WGS), and large panel sequencing data, the bioinformatics division of QIAGEN, QIAGEN Digital Insights, improved QIAGEN CLC Genomics Workbench Premium, which removes the data-analysis obstacles of next-generation sequencing (NGS).
• On May 16, 2022, A no-cost program for the annotation, characterisation, and visualization of specific antibodies will be made available by Geneious Biologics. The Geneious Biologics antibody annotation's potency can be personally experienced by researchers thanks to the online free antibody sequence analysis tool.

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Softberry, Inc., Illumina, Inc., QIAGEN, GenScript, DNASTAR, BGI,Geneious, Sangamo Therapeutics and Takara Bio Inc..

Why Purchase the Report?
• To visualize the global gene prediction tool market segmentation based on component, method, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of gene prediction tool market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global gene prediction tool market report would provide approximately 69 tables, 66 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies